ES2527200T3 - Modulación del crecimiento de las bífidobacterias mediante una combinación de oligosacáridos de la leche humana - Google Patents

Modulación del crecimiento de las bífidobacterias mediante una combinación de oligosacáridos de la leche humana Download PDF

Info

Publication number
ES2527200T3
ES2527200T3 ES12707135.5T ES12707135T ES2527200T3 ES 2527200 T3 ES2527200 T3 ES 2527200T3 ES 12707135 T ES12707135 T ES 12707135T ES 2527200 T3 ES2527200 T3 ES 2527200T3
Authority
ES
Spain
Prior art keywords
bifidobacteria
oligosaccharides
modulation
growth
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12707135.5T
Other languages
English (en)
Other versions
ES2527200T5 (es
Inventor
David Curtis Frantz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nestec SA
Original Assignee
Nestec SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45809349&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2527200(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nestec SA filed Critical Nestec SA
Publication of ES2527200T3 publication Critical patent/ES2527200T3/es
Application granted granted Critical
Publication of ES2527200T5 publication Critical patent/ES2527200T5/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
    • A23C9/1307—Milk products or derivatives; Fruit or vegetable juices; Sugars, sugar alcohols, sweeteners; Oligosaccharides; Organic acids or salts thereof or acidifying agents; Flavours, dyes or pigments; Inert or aerosol gases; Carbonation methods
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pediatric Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dairy Products (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Formulación prebiótica para administración oral a un humano, que lleva 2'-fucosil-lactosa, 6'-sialil-lactosa y 3'- sialil-lactosa y en la cual la proporción en peso de 3'-sialil-lactosa es, como mínimo, igual a la de 2'-fucosil-lactosa.

Description

imagen1
imagen2
imagen3
imagen4
imagen5

Claims (1)

  1. imagen1
ES12707135T 2011-02-10 2012-02-03 Modulación del crecimiento de las bífidobacterias mediante una combinación de oligosacáridos de la leche humana Active ES2527200T5 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161441451P 2011-02-10 2011-02-10
US201161441451P 2011-02-10
PCT/IB2012/050511 WO2012107865A2 (en) 2011-02-10 2012-02-03 Modulation of growth of bifidobacteria using a combination of oligosaccharides found in human milk

Publications (2)

Publication Number Publication Date
ES2527200T3 true ES2527200T3 (es) 2015-01-21
ES2527200T5 ES2527200T5 (es) 2022-12-29

Family

ID=45809349

Family Applications (2)

Application Number Title Priority Date Filing Date
ES14177597.3T Active ES2692533T3 (es) 2011-02-10 2012-02-03 Modulación del crecimiento de las bífidobacterias mediante una combinación de oligosacáridos de la leche humana
ES12707135T Active ES2527200T5 (es) 2011-02-10 2012-02-03 Modulación del crecimiento de las bífidobacterias mediante una combinación de oligosacáridos de la leche humana

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES14177597.3T Active ES2692533T3 (es) 2011-02-10 2012-02-03 Modulación del crecimiento de las bífidobacterias mediante una combinación de oligosacáridos de la leche humana

Country Status (19)

Country Link
US (3) US20140371173A1 (es)
EP (2) EP2672844B2 (es)
CN (2) CN104126749A (es)
AU (1) AU2012215042B2 (es)
BR (1) BR112013020108A2 (es)
CA (1) CA2825697A1 (es)
CL (1) CL2013002210A1 (es)
ES (2) ES2692533T3 (es)
IL (1) IL227487A (es)
MX (2) MX362129B (es)
MY (1) MY161034A (es)
PH (1) PH12013501501A1 (es)
PL (1) PL2672844T3 (es)
PT (1) PT2672844E (es)
RU (1) RU2586928C2 (es)
SG (1) SG192095A1 (es)
TW (1) TW201244640A (es)
WO (1) WO2012107865A2 (es)
ZA (1) ZA201306751B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012215042B2 (en) 2011-02-10 2016-01-14 Société des Produits Nestlé S.A. Modulation of growth of bifidobacteria using a combination of oligosaccharides found in human milk
PT2734049T (pt) 2011-06-20 2018-07-24 Heinz Co Brands H J Llc Composições e métodos probióticos
MX2014012362A (es) * 2012-04-13 2015-05-07 Trustees Boston College Composición prebiótica y métodos de uso.
EP2708145B1 (en) 2012-09-14 2016-05-04 Abbott Laboratories Nutritional compositions for use in methods for modulating corticosterone levels in psychologically stressed individuals
HK1231398A1 (zh) 2014-04-08 2017-12-22 Abbott Laboratories 使用人乳寡糖增强对病原体的粘膜先天免疫反应和/或检测的方法
CN107249611A (zh) * 2014-10-24 2017-10-13 进化生物系统股份有限公司 活化的双歧杆菌及其应用方法
WO2016086151A1 (en) * 2014-11-26 2016-06-02 Abbott Laboratories Infant formula with rrr-alpha-tocopherol, 2'-fucosyllactose, and a probiotic
WO2016086157A1 (en) * 2014-11-26 2016-06-02 Abbott Laboratories Infant formula comprising human milk oligosaccharides, polyunsaturated fatty acids, nucleotides, and lutein
CN107106584A (zh) * 2014-12-08 2017-08-29 格礼卡姆股份公司 用于治疗代谢障碍的合成组合物
US10835544B2 (en) 2014-12-08 2020-11-17 Glycom A/S Synthetic composition for regulating satiety
US10881674B2 (en) 2014-12-08 2021-01-05 Glycom A/S Synthetic composition for treating metabolic disorders
US10987368B2 (en) 2014-12-08 2021-04-27 Glycom A/S Synthetic composition for preventing or treating CVD
PT3264922T (pt) * 2015-03-05 2025-01-07 Nestle Sa Composições para utilização na melhoria da consistência ou frequência das fezes em lactentes ou crianças pequenas
US10780103B2 (en) 2015-10-28 2020-09-22 Glycom A/S Synthetic composition and method for modulating emotion and mood disorders
WO2017071715A1 (en) 2015-10-28 2017-05-04 Glycom A/S Synthetic composition and method for modulating brain function and behaviour
CN108541221B (zh) * 2015-12-15 2023-02-28 格礼卡姆股份公司 Hmo的混合物
CN109561724A (zh) 2016-06-21 2019-04-02 阿拉食品公司 生产含乳蛋白和乳糖类的改良营养产品的方法及通过该方法获得的产品
CA3030809A1 (en) * 2016-07-28 2018-02-01 Fonterra Co-Operative Group Limited Sialyloligosaccharide product and process
RU2765232C1 (ru) * 2017-06-21 2022-01-26 Эбботт Лабораториз Способ улучшения роста полезных бактерий в желудочно-кишечном тракте
EP3716983A4 (en) * 2017-11-30 2022-03-02 Glycom A/S HUMAN MILK OLIGOSACCHARIDES AND SYNTHETIC COMPOSITIONS THEREOF FOR MICROBIOTA MODULATION
CN122556668A (zh) * 2019-06-05 2026-08-14 森永乳业株式会社 双歧杆菌属细菌增殖促进用组合物
JP7474596B2 (ja) * 2020-01-20 2024-04-25 森永乳業株式会社 新規ビフィドバクテリウム属細菌、および当該細菌を含む組成物、並びに当該細菌の増殖促進用の組成物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260280A (en) 1989-02-07 1993-11-09 Snow Brand Milk Products Co., Ltd. Bacterial toxin neutralizer
MXPA02008016A (es) * 2000-02-17 2002-11-29 American Home Prod Formulacion nutricional que contiene substancias prebioticas.
WO2001060246A2 (en) * 2000-02-18 2001-08-23 Argose, Inc. Multivariate analysis of green to ultraviolet spectra of cell and tissue samples
US6913778B2 (en) 2001-12-21 2005-07-05 Wyeth Infant formula compositions comprising increased amounts of alpha-lactalbumin
US7867541B2 (en) 2003-04-14 2011-01-11 Mead Johnson Nutrition Company Compositions and methods of formulation for enteral formulas containing sialic acid
CN1863463B (zh) * 2003-06-23 2011-05-04 雀巢技术公司 用于促进肠道屏障成熟的营养组合物
WO2005055944A2 (en) † 2003-12-05 2005-06-23 Cincinnati Children's Hospital Medical Center Oligosaccharide compositions and use thereof in the treatment of infection
CA2628225C (en) 2005-11-04 2014-06-17 Hans Henrik Holst A concentrate derived from a milk product enriched in naturally occurring sialyllactose and a process for preparation thereof
WO2007114683A1 (en) * 2006-03-30 2007-10-11 N.V. Nutricia Milk oligosaccharides for stimulating the immune system
EP2060257A1 (en) * 2007-11-08 2009-05-20 Nestec S.A. Prevention and treatment of secondary infections following viral infection
EP2072052A1 (en) 2007-12-17 2009-06-24 Nestec S.A. Prevention of opportunistic infections in immune-compromised subjects
NL2001377C2 (nl) 2008-03-14 2009-09-15 Friesland Brands Bv Werkwijze voor het isoleren van siaalzuur bevattende oligosachariden, alsmede de hiermee verkrijgbare siaalzuur bevattende oligosachariden bevatttende samenstellingen.
EP2459202A1 (en) * 2009-07-31 2012-06-06 Nestec S.A. Nutritional composition for breast-fed infants or pets with probiotics and selected nutrients
NL2004200C2 (en) * 2010-02-05 2011-08-08 Friesland Brands Bv Use of sialyl oligosaccharides in weight management.
WO2011136647A1 (en) * 2010-04-27 2011-11-03 N.V. Nutricia Use of 6'-sialyl lactose in infant and toddler nutrition
MX356184B (es) * 2010-12-31 2018-05-17 Abbott Lab Fórmulación pediátrica sintética que comprende un probiótico.
AU2012215042B2 (en) 2011-02-10 2016-01-14 Société des Produits Nestlé S.A. Modulation of growth of bifidobacteria using a combination of oligosaccharides found in human milk

Also Published As

Publication number Publication date
EP2792252A2 (en) 2014-10-22
AU2012215042B2 (en) 2016-01-14
EP2672844A2 (en) 2013-12-18
CL2013002210A1 (es) 2014-01-10
EP2792252A3 (en) 2015-03-25
CA2825697A1 (en) 2012-08-16
ES2692533T3 (es) 2018-12-04
IL227487A (en) 2015-10-29
EP2672844B2 (en) 2022-10-05
MX2013009087A (es) 2013-09-13
EP2672844B1 (en) 2014-11-19
PH12013501501A1 (en) 2019-10-07
EP2792252B1 (en) 2018-09-12
BR112013020108A2 (pt) 2017-06-13
RU2013141449A (ru) 2015-03-20
IL227487A0 (en) 2013-09-30
SG192095A1 (en) 2013-08-30
TW201244640A (en) 2012-11-16
ZA201306751B (en) 2015-05-27
CN104126749A (zh) 2014-11-05
WO2012107865A2 (en) 2012-08-16
PL2672844T3 (pl) 2015-04-30
RU2586928C2 (ru) 2016-06-10
US20150141367A1 (en) 2015-05-21
PT2672844E (pt) 2015-02-04
US20140371173A1 (en) 2014-12-18
MY161034A (en) 2017-04-14
US20120208782A1 (en) 2012-08-16
WO2012107865A3 (en) 2012-11-01
MX362129B (es) 2019-01-07
CN103347405A (zh) 2013-10-09
MX345413B (es) 2017-01-27
ES2527200T5 (es) 2022-12-29

Similar Documents

Publication Publication Date Title
MX345413B (es) Modulacion del crecimiento de bifidobacterias mediante el uso de una combinacion de oligosacaridos que se encuentran en la leche humana.
CY1123476T1 (el) Τροποποιητες πυρηνικης μεταφορας και χρησεις αυτων
MX2013007675A (es) Combinacion simbiotica de oligosacaridos probioticos y de leche humana para promover el crecimiento de la microbiota beneficiosa.
DOP2012000324A (es) Composiciones farmaceuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4metil-piperazin-1il)-1h-bencimidazol-2-il)-1h-quinolin-2-ona
MX2023002494A (es) Oligosacaridos de leche humana para modular la inflamacion.
MX2015007933A (es) Oligosacaridos de leche humana para mejorar sintomas de estres.
IT1400982B1 (it) Collirio osmotico trans-epiteliale per la cura del cheratocono.
CO6640262A2 (es) Composiciones farmacéuticas y métodos para su elaboración
BR112015020389A8 (pt) compostos carbazol úteis como inibidores de bromodomínio, seu uso, bem como composição e produto farmacêuticos compreendendo os mesmos
PE20151437A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
EA201401077A1 (ru) Биспецифические антитела к человеческому tweak и человеческому il17 и их применения
ES2574417T3 (es) Composición de gel
CR20130239A (es) Compuestos de triazolopiridina
PE20151416A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
MX2012004869A (es) Formulaciones espesantes estables.
MX360554B (es) Composiciones que comprenden y metodos que utilizan inhibidores de co-transportadores de glucosa-sodio 1 y 2.
MX2016013245A (es) Regimen de dosificacion de liberacion inmediata de moduladores s1p.
BR112016007414A2 (pt) método de produção de um comprimido de monocamada, e, comprimido de monocamada
MX340983B (es) Composiciones farmaceuticas y nutraceuticas de acido abscisico.
ES2616035T3 (es) Preparación para su uso en la profilaxis y el tratamiento de osteoporosis atípica
ES2619428T3 (es) Composición en polvo para desinfección de las ubres de los animales lecheros
MX2015010486A (es) Composicion masticable para administracion oral y proceso para preparar la misma.
AR089060A1 (es) Composiciones para el cuidado bucal
CL2013003588A1 (es) Composicion farmaceutica en forma de suspension oral que comprende como principio activo una fraccion de flavonoide y como excipiente goma de xantano en la cantidad de 0,30 %p/p a 0,60 %p/p; uso para el tratamiento de la insuficiencia venosa.
UY35037A (es) Composición antiparasitaria de amplio espectro de nitazoxanida,probióticos y prebióticos